

ChromoGenics

Interim Report January–June 2023

A photograph of a modern glass skyscraper at dusk. The building's facade is composed of large glass panels that reflect the twilight sky. The Crayon logo, featuring a stylized infinity symbol above the word "Crayon", is mounted vertically on the upper part of the building. The ground floor has a glass entrance with a canopy. A street lamp and a small tree are visible in the foreground. The sky is a deep blue, and the overall scene is illuminated by the warm lights of the building and street.

Crayon

ChromoGenics invests in the future with increased marketing initiatives and continued cost focus

Q2 2023

- On April 21, ChromoGenics announced that the Board of Directors had decided to postpone the Annual General Meeting until June 27 and the delivery and publication of the Annual Report for 2022 until June 6.
- On May 3, ChromoGenics announced that it had signed a letter of intent with Future Glass of the United Arab Emirates regarding manufacturing, marketing and distribution of the dynamic glass ConverLight® Dynamic.
- On May 9, ChromoGenics announced that it is starting a cooperation with Thomsa Glass and receiving a small strategic order from the Netherlands for ConverLight® Dynamic glass.
- While waiting for a decision from the insurance companies, the company has agreed with the property owner at Gullhaug Torg 5 in Norway on a loan amounting to a maximum of SEK 5 million, which will be paid out as costs are incurred, in order to cover the expenses linked to replacing damaged glass. The interest on the loan is 7.5%. The entire loan does not need to be used.
- On May 17, ChromoGenics announced that its Board of Directors resolved, subject to subsequent approval by the Company's Annual General Meeting on June 21, 2023, to carry out a new issue of shares and warrants ("units") with preferential rights for the Company's existing shareholders. The rights issue consists of not more than 300,432,678 new shares and not more than 300,432,678 warrants. The subscription price has been set at SEK 0.1 per unit, which corresponds to a subscription price of SEK 0.1 per share.

The rights issue, which is covered up to approximately 80 percent by subscription commitments and issue guarantees, will, upon full subscription, initially provide ChromoGenics with approximately SEK 30 million before transaction costs related to the rights issue. In the event of full subscription and that all warrants within the framework of issued units are fully exercised, the Company may receive an additional capital contribution of approximately SEK 30 million, based on a subscription price corresponding to the subscription price in the rights issue. In order to ensure its financing needs until the rights issue is completed, the company has taken up a loan facility of SEK 10 million at market terms.

The Board of Directors of ChromoGenics resolves to bring forward the Annual General Meeting, from June 27, 2023, to June 21, 2023, and change the date for publication of the annual report for 2022, from June 6, 2023, to May 31, 2023.

- In March, ChromoGenics announced that the company's CFO had decided to take on new challenges, and on May 17 ChromoGenics announced that the appointed interim CFO, Anne-Marie Gullman, would take office on June 12.
- On May 25, the company is publishing its report for Q1 2023.
- On May 31, the company is publishing its annual report for 2022.

- On June 21, the company is holding its Annual General Meeting and will publish on the same day a bulletin from this Meeting and that the Meeting resolved to conduct the new issue proposed by the Board of Directors. The prospectus relating to the new issue will be published on the same day.

Earnings performance in summary

<i>MSEK</i>	2023	2022	2023	2022	2022
	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Net sales	3,7	2,8	9,5	11,3	18,3
EBITDA	-10,2	-13,9	-21,5	-30,0	-52,6
Net income	-11,9	-15,6	-24,9	-33,2	-57,0
EPS before dilution, SEK	-0,07	-0,9	-0,1	-1,95	-1,6
Cash and cash equivalents at end of period	5,7	22,9	5,7	22,9	16,7

Events after the end of the reporting period

- Rights will be traded during the period June 28–July 7
- The subscription period will run during the period June 28–July 12
- ChromoGenics will announce the outcome of the rights issue on July 14. The Rights Issue was 56.0 percent subscribed for with and without the support of unit rights. In total, 167,157,849 units were subscribed for with the support of unit rights, representing approximately 55.6 percent of the Rights Issue, and 1,045,519 units were subscribed for without the support of unit rights, representing approximately 0.3 percent of the Rights Issue. The remaining guaranteed part of the Rights Issue, corresponding to 72,019,594 units or approximately 24.0 percent, will be allocated to guarantors and ChromoGenics will thereby receive a total of approximately SEK 24.0 million before issue costs.

Comments from the CEO

ChromoGenics is a proptech company that contributes to more daylight and well-being indoors, higher energy efficiency, and a decreased footprint for the real estate industry.



Uncertainty in the construction and real estate industry, primarily in Sweden, continued during the quarter, which, combined with higher financing costs, led to a decrease in the number of buildings starts. The summer has seen record-high temperatures and power disruptions throughout the world, particularly in southern Europe. The impact of the changing climate has become a reality for more and more people.

ChromoGenics has the market's most sustainable solution that contributes to lower electricity consumption, decreased CO₂ emissions, and, in particular, lower peak consumption when temps are at their warmest. It will become more important to reduce peak consumption to ensure the functionality of power grids, particularly in southern Europe and the USA, and we can contribute to this with concrete and measurable solutions.

Focus on sales

During the quarter, we continued to have a high level of activity in sales and marketing. We received several smaller orders from new markets, the United Arab Emirates, the

Netherlands, Germany, France and Greece. These are admittedly smaller projects, but important steps that bode well for the future since they come from new partners who are demonstrating their confidence in us by using our technology.

New collaborations were started with Thomsa Glass in Benelux and Future Glass in the United Arab Emirates. We also received a first small order from the German window manufacturer Enersign, which specializes in premium windows for sustainable properties and passive houses and has sales in Europe and North America. These are interesting segments for us.

We are involved in a growing number of large projects, both in Sweden and abroad. We are not seeing that we are losing projects, but the decision-making process is taking time, which has negatively impacted our order intake.

Currently, we do not view growing our sales organization as the right path for us to increase our sales. We have good activity in Sweden and Norway with our own sales staff. Internationally, we continue to believe that the right path for us is to collaborate with competent companies in the glass industry and benefit from their regional networks, trust and customer relationships.

We see positive development in several markets with good growth in inquiries. However, it has taken longer than we have wanted to convert to booked orders.

We are now preparing a digital marketing campaign with the aim of driving sales of and raising awareness for ConverLight in select European markets. The campaign will launch in the fall.

Stability and cost control

Since March, our production has been reliable and robust, and we feel that we have resolved many of the challenges we have wrestled with previously. We manufactured dynamic glass for two assisted living residences in Sweden, a segment where we would like to grow. We also manufactured glass for a small number of projects in Germany, the Netherlands, Abu Dhabi and France. The cost of raw materials relative to net sales, adjusted for inventory changes, continues to improve.

Despite high inflation, we lowered our overhead somewhat. We also succeeded in stabilizing production without making additional investments. Today, we see that our machine park has the potential to deliver very good profitability for the company without further investments as sales increase.

Both earnings and cash flow improved by around SEK 4 million in the quarter, despite relatively weak sales.

During the quarter, we carried out a rights issue to be able to continue with our market expansion. We are proud and grateful for the confidence our shareholders are showing in us, not least that almost all major owners participated in the issue.

We thus have a good starting point to grow and improve the result: Stability in production and a sought-after product that is relevant and ISO-tested. Our full focus is now on converting customer interest into booked orders and thus growing toward profitability and positive cash flow.

Fredrik Fränding, CEO

Q2 2023 – April–June

NET SALES


In Q2 2023, ChromoGenics' net sales amounted to SEK 3.8 (2.8) million, an increase of SEK 0.9 million compared to the corresponding quarter in 2022. In Q2 2023, the company noted an increase in sales of its main product, ConverLight Dynamic, by SEK 2.3 million compared to the corresponding quarter in 2022. The company's other product, ConverLight Static, posted during the same period a decrease in sales of just over SEK 1.1 million.

During the quarter, the company, among other orders, manufactured and invoiced dynamic glass for two assisted living residences in Sweden: Willhelmsrogården and Katedern in Gamleby. The company also manufactured and invoiced a number of smaller projects in Germany, the Netherlands, Abu Dhabi and France and manufactured glass for a hospital in Greece as part of the EU project Switch2Save.

The change in inventory amounts to SEK 1.8 (-0.5) million. The company successfully limited its purchases of raw materials in order to avoid inventory build-up. The increase in inventory mainly consists of the processing of raw materials into semi-finished products or "products in progress." The improved stability in production has meant that our inventory now includes semi-finished products in the form of sputtered thin films. Production of replacement glass for the insurance case in Norway also contributed to the increase in inventory.


Work performed for the company's own use and capitalized, which refers to development linked to the development of new products, was largely unchanged and amounted to SEK 0.6 (0.6) million.

The company's total revenue in the second quarter increased by just over SEK 3 million to SEK 6.3 (3.2) million.



ORDER INTAKE

Order intake for Q2 2023 was SEK 2.1 (7.6) million and consisted of smaller orders of mainly ConverLight Dynamic from, among others, Abu Dhabi, the Netherlands and Germany. The economic downturn in the construction sector negatively impacted order intake. However, the company is involved in a number of large projects in Sweden and abroad and makes the assessment that the conditions for strengthening order intake are good in coming quarters. The company's focus continues to be on increasing the conversion rate of interest and business opportunities to booked orders.



COST DEVELOPMENT

In Q2 2023, the company continued to focus on cost efficiency, adopting a restrictive approach to costs in general and continuing efforts to reduce costs. The production of ConverLight® Dynamic continued to use ITO manufactured in-house, a process that began in the second half of 2022. At the start of 2023, the company's production continued to be impacted by the challenges the company experienced at the end of 2022, which led to increased scrapping and in turn had a negative impact on raw materials and consumables. Since the beginning of March 2023, however, the company's production has worked well and is in line with the action plan previously adopted. Because the company has been able to deliver according to plan in recent months, costs for raw materials and consumables were lower than in Q1 2023 and slightly lower than in Q2 2022.

No redeliveries were made in Q1 2023, but a small delivery of faulty glass was replaced in the second quarter. The faulty glass had been manufactured before the company started in-house production of sputtered film in June 2021 and has now been replaced with newly manufactured glass. Approximately SEK 0.3 (1.2) million was therefore drawn against the provision for redeliveries in the period. The provision for redeliveries amounted thus at the end of the period to SEK 8.1 (20.2) million.

Despite high inflation, a negative exchange rate and a generally higher cost profile, other external costs decreased by SEK 0.3 million during the second quarter and amounted to SEK 6.9 (7.2) million. By continuing its focus in the second quarter on cost efficiency, the company lowered its costs for agency personnel to SEK 1.4 million, which was offset by increased costs for patents, repairs and maintenance of machines and electricity.

The company's ongoing insurance case related to the installation at Gullhaug Torg 5 in Oslo is under investigation by the involved insurance companies. The case concerns damages to installed glass that are deemed to have been caused by an error at a subcontractor. The company's assessment continues to be that the cost of repairing the damages will be covered by insurance. The company views the matter to be a contingent liability and has not created a provision for either costs or income from insurance.

Personnel costs in the second quarter amounted to SEK 6.5 million compared to SEK 7.0 million in the corresponding period the previous year. The reduction is attributable to the personnel mix and lower recruitment costs. The average number of employees in Q2 2023 amounted to 33 (38).

Depreciation on non-current assets amounted to SEK 0.9 (0.9) million in Q2 2023. The company applies a production-dependent depreciation method where depreciation is charged at the rate units are produced. The company raised the depreciation rate in Q3 2022, which explains the increase in depreciation compared to the corresponding quarter in 2022.

ChromoGenics' operating loss for the second quarter of the year amounted to SEK -11.1 (-14.8) million, which is an improvement of SEK 3.7 million compared to the corresponding period in 2022.

Net financial items for the second quarter were SEK -0.8 (-0.8) million and are mainly related to interest costs for the conditional loans from the Swedish Energy Agency and where the interest expense was impacted by the increase in the Riksbank's reference rate.

Profit/loss for Q2 2023 amounted thus to SEK -11.9 (-15.6) million, an improvement of SEK 3.7 million compared to the corresponding period in 2022.

CASH FLOW IN Q2

Cash flow from operating activities before changes in working capital amounted to SEK -10.5 (-14.7) million, an improvement of SEK 4.2 million compared to Q2 2022. The improvement is driven by the improved operating profit during the quarter.

Cash flow from operating activities including a change in working capital amounted to SEK -15.1 (-22.9) million for the second quarter of the year, of which the cash flow from the change in working capital amounted to SEK 4.6 million. The change in working capital is mainly attributable to reduced accounts payable of SEK 2.9 million, an increase in inventory of SEK -1.4 million, and reduced accounts receivable of SEK 1.4 million.

Net cash flow from investing activities amounted to SEK -0.2 (-3.0) million in Q2 2023. Investments in intangible assets amounted to SEK -0.2 (-2.2) million and are related to the development of new products. The acquisition of property, plant and equipment amounted to SEK 0.0 (0.0) million.

Net cash flow from financing activities amounted to SEK 4.3 (-0.5) million in Q2 2023. The positive cash flow from financing activities is mainly attributable to bridge loans raised prior to new issues. The comparison figures for Q2 2022 include the rights issue that was completed at the start of 2022.

Cash at the end of the period amounted to SEK 5.6 million compared to SEK 22.9 million for the corresponding period in 2022.

FINANCIAL POSITION

Cash and bank balances amounted to SEK 5.7 million on June 30, 2023, compared to SEK 22.9 million on June 30, 2022. This represents a decrease in cash and bank balances of SEK 17.2 million over the past twelve months. Cash and bank balances include frozen funds linked to a bank guarantee for projects of approximately SEK 0.9 million. The company expects the ongoing new issue to strengthen cash by SEK 24 million before issue expenses, which would make the company's financial position the same in Q2 2023 and Q2 2022.

Equity at the end of the period amounted to SEK 51 million, of which restricted equity amounted to SEK 43.6 million and unrestricted equity to SEK 7 million. For the same period in 2022, equity amounted to SEK 69.0 million.

ChromoGenics was granted in 2022 an extended deferment until October 1, 2025, for its repayment obligation on the conditional loans from the Swedish Energy Agency. Given the extended deferment, the loans were reclassified from current liabilities to non-current liabilities. As at March 31, 2022, the debt in its entirety was classified as a long-term liability. The loan is subject to a condition of an additional status update and reporting in August 2024, at which point the Swedish Energy Agency is entitled to reconsider the decision. Long-term liabilities amounted to SEK 69.2 (50.6) million as at June 30, 2023.

Current liabilities amounted on the balance sheet date to SEK 23 (52) million.

INVESTMENTS

Investments during Q2 2023 amounted to SEK 0.2 (3.3) million and are exclusively attributable to intangible fixed assets related to the development of new products. The acquisition of property, plant and equipment amounted to SEK 0.0 (0.8) million.

EMPLOYEES

The average number of employees in Q2 2023 was 33 (38). The average, including agency personnel and consultants, was 36 (47), which is 11 fewer than in the corresponding period in 2022. The number of employees amounted to 31 as at June 30, 2023, and was the same as at June 30, 2022.

SHARE CAPITAL

The outcome of the proposed rights issue, which was later resolved upon by the General Meeting and runs from June 28 to July 12, is not known at the time of this interim report and therefore could not be taken into account. The outcome will be reported in the Q3 interim report.

The preferential rights issue carried out in Q4 2022 was registered with the Swedish Companies Registration Office on December 15, 2022. The subscription period for the warrants, TO 4 and TO 5, respectively, issued in connection with the two preferential rights issues carried out in 2022, was March 13–27, 2023. Due to exercised warrants, the total number of shares in ChromoGenics increased by 28,870,681, from 142,805,135 to 171,675,816. The share capital in ChromoGenics increased by SEK 5,774,136.20, from SEK 28,561,027.00 to SEK 34,335,163.20. As of March 31, 2023, the registration with the Swedish Companies Registration Office regarding the exercised warrants had not been completed, which meant that the exercised warrants had been replaced with interim shares.

H1 2023 – January–June

Net sales during the period decreased by approximately SEK 1.7 million compared to the corresponding period the previous year. This change derives primarily from a drop in export sales of approximately SEK 6.4 million. However, approximately half of this was offset by an increase in domestic sales. There was no project in 2023 that could compare to the Gullhaug Torg 5 project in Oslo that was delivered in 2022, although the Franska Skolan project in Copenhagen was able to compensate to some extent for the decrease compared to 2022.

Change in inventory amounts to SEK 2.9 million and is primarily attributable to an increase in processed inventory in the form of products in progress and increased inventory of finished goods through in-house production of sputtered film. The company's production was impacted mainly during Q1 2023 by the challenges the company experienced at the end of 2022 and increased scrapping.

Other operating income decreased to SEK 267,000 in H1 2023 compared to SEK 808,000 in the corresponding period in 2022. Exchange rate fluctuations are the primary cause for the decrease in income as a result of a less favorable exchange rate between the Swedish krona and the euro.

Order intake through June 2023 amounts to SEK 4.6 (8.3) million. The decrease of SEK 3.7 million is partly due to the booking of an order for Franska Skolan in Copenhagen in H1 2022. The company has not booked a project of the same size in H1 2023.

Despite high inflation and a negative exchange rate trend, total operating costs during the first half of the year amounted to SEK -36.6 (-44.1) million, a decrease of SEK 7.8 million that is mainly due to increased cost efficiency in the form of lower costs in general thanks to, among other things, positive effects from in-house production of sputtered film.

Profit/loss for H1 2023 amounts to SEK -24.9 (-33.2) million, an improvement of SEK 8.3 million compared to the corresponding period in 2022. This improvement is mainly due to an increased focus on costs, which lowered costs in H1 to SEK 7.8 million and slightly improved income to SEK 0.5 million.

The balance sheet total at the end of the period on June 30, 2023, amounted to SEK 143.6 (171.9) million, a decrease of SEK 28.3 million over twelve months. The company's fixed assets decreased by SEK 1.6 million to SEK 101.7 (103.3) million over the period compared to one year ago. Current assets decreased by SEK 24 million compared to the same period in 2022, mainly due to the company completing and receiving cash from a new share issue in June 2022. This can be seen in cash and cash equivalents, which are currently SEK 17.2 million lower than at the same point in time in 2022. Among other current assets, inventory decreased by SEK 5.4 million and accounts receivable decreased by SEK 3.3 million.

Investments during the first half of the year amounted to SEK 0.2 (4.2) million and are attributable to intangible fixed assets related to the development of new products.

The average number of employees during the first half of the year was 32 (34), a decrease of 2. The number of employees including agency personnel and consultants amounted to 35 (47), a decrease of 12.

Equity at the end of the period amounted to SEK 51 (69) million, of which restricted equity amounted to SEK 43.6 (12.76) million.

Shareholders

Since March 23, 2017, ChromoGenics' shares and warrants have been traded on Nasdaq First North Growth Market. Vator Securities has been the Certified Adviser since February 26, 2023.

The largest shareholders, excluding interim shares, as at June 30, 2023, are presented below:

Shareholders excl interim shares as of 2023-06-30	Holdings	Votes & capital %
Färna Invest AB	30 328 751	17,7
Investment Aktiebolaget Balticum	9 009 434	5,3
Avanza Pension	6 889 355	4,0
Parment Förvaltning AB	6 112 136	3,6
Brandt, Barbro	5 096 000	3,0
Jeansson, Theodor	4 000 000	2,3
AS SEB Pank, NQI	3 963 096	2,3
Bengt Josefsson Utveckling AB	3 400 000	2,0
RGG ADM-Gruppen AB	2 893 623	1,7
Movestic Livförsäkring AB	2 591 118	1,5
Övriga	97 392 303	56,7
Totalt	171 675 816	100,0

Number of shareholders as at 6/30/2023:

6,145

Source: Euroclear Sweden AB

Significant risks and uncertainty factors

The company is exposed to a number of financial risks: liquidity risk, credit risk and currency risk. The Board of Directors and the company's management team strive to manage these risks by identifying, evaluating and, where appropriate, offsetting and counteracting them on a regular basis. For more information, see [2022 Annual Report](#).

Liquidity risk

ChromoGenics' future capital needs are determined by a large number of factors, such as the planned rate of expansion, product and process development, investment needs, and the company's sales development and achieved gross margins. The economy and the interest rate can also influence customers' investment decisions.

The Board of Directors reviews on a regular basis the company's existing and forecast cash flows to ensure that the company has the means and resources required to conduct business and maintain the strategic direction adopted by the Board. The company's long-term need for cash is determined by how successful the company will be at increasing its sales, directly but also through the new cooperation agreements entered into during Q1 2023.

At the end of June 2023, the company's cash and cash equivalents amounted to SEK 5.7 million, and current assets totaled approximately SEK 20 million, excluding cash and cash equivalents. Equity amounted to SEK 51 million at the end of the period. The rights issue completed in July is expected to raise an additional SEK 24 million for the company before issue expenses, and an additional capital contribution of a maximum of SEK 20 million is expected in the fourth quarter via the warrants linked to the new issue that was recently completed.

Based on the current adopted strategic plan, the Board of Directors makes the assessment that the company may need additional liquidity contributions in the coming 12-month period. Given this financing need, the Board of Directors is currently evaluating different financing alternatives. Financing in turn can be raised from different sources and carried out in different ways depending on prevailing market conditions. Based on the improved production outcome, increased cooperation with new partners, and pending marketing campaigns, the Board of Directors notes that the company has reached key operational and strategic milestones during 2023.

Given this, the Board of Directors continues to see good possibilities for successfully securing long-term financing for the company. If the company's cash and cash equivalents do not cover the need for financing up until the point in time when the company achieves a positive cash flow from its operating activities, and if the company does not successfully secure long-term financing, there is a risk that this ultimately will lead to the winding down of the company.

Currency risk

Normally, a significant portion of the company's sales is in SEK. If there are sales in USD, EUR and/or NOK, and these currencies appreciate against SEK, this will have a positive effect. A significant percentage of the material and process costs currently occur in USD and EUR and are translated/reported into SEK on payment days. If USD and/or EUR appreciates against SEK, this will have a negative effect on the company's costs. The company is thus directly dependent on the exchange rates of these currencies. Given that the exchange rate exposure is currently relatively limited, this risk is managed without special currency hedging.

Employees

ChromoGenics currently has an organization of approximately 35 employees, including agency personnel and consultants, and is dependent on a number of key staff members. A weak financial position and weak profitability during the company's growth phase can limit the possibility of recruiting and keeping key staff members.

AUDITOR'S REVIEW

This interim report has not been audited by the company's auditor.

FINANCIAL CALENDAR

August 25, 2023	Interim Report January–June 2023
November 23, 2023	Interim Report January–September 2023
February 20, 2024	Year-End Report 2023
May 2024	Interim Report January–March 2024

The Board of Directors and CEO hereby confirm that the interim report provides a fair and accurate view of the company's operations, position and performance and describes the significant risks and uncertainty factors facing the company.

Uppsala, August 25, 2023

ChromoGenics AB (publ) CIN 556630-1809

Anders Brännström
Board member

Johan Hedin
Chair of the Board of Directors

Sirpa Engman
Board member

Fredrik Andersson
Board member

Andreas Jaeger
Board member

Fredrik Fränding
CEO

For more information, please contact:

Fredrik Fränding, CEO: +46 72 249 24 62

Anne-Marie Gullman, CFO & Head of Investor Relations: +46 76 136 01 15

This report, together with previously published interim reports, is available in its entirety on the company's website.

<https://chromogenics.com/sv/finansiella-rapporter/>

This information constitutes such information that ChromoGenics AB is obligated to disclose in accordance with the EU Market Abuse Regulation. The information was submitted by the above-mentioned contact persons for publication on August 25, 2023, at 8:30 AM CET.

ABOUT CHROMOGENICS

ChromoGenics is a proptech company producing smart dynamic glass that improves indoor environments and well-being and lowers buildings' energy consumption, operating expenses and impact on the climate. The company's product ConverLight® Dynamic is based on a unique patented technology from the Ångström Laboratory in Uppsala, where electrochromic coatings are sputtered onto plastic film. The result is a dynamic film that can be laminated between glass layers, which provides buildings with good solar protection and lowered environmental impact from production, transport and use. The dynamic film is easy to transport and can be applied by local partners in the glass industry, which means it is possible to avoid long-distance shipping of bulky glass. All of ChromoGenics' products strive to follow the key words *environment* and *health*. This means a focus on environmentally friendly material, lower energy consumption, increased access to daylight and views and improved indoor comfort.

The company's production facilities in Uppsala have been financed in part by a conditional loan from the Swedish Energy Agency. ChromoGenics' share (CHRO) is listed on Nasdaq First North Growth Market, and Vator Securities is the Certified Adviser.

info@chromogenics.com

Certified Adviser: Vator Securities

Financial Statements:

Income Statement

Balance Sheet

Statement of Cash Flows

Statement of Changes in Equity

Notes

Income Statement per Individual Quarter

Profit & Loss Statement					
KSEK	2023 Apr-Jun	2022 Apr-Jun	2023 Jan-Jun	2022 Jan-Jun	2022 Jan-Dec
Net sales	3 741	2 802	9 541	11 317	18 260
Change in inventories of products in progress	1 829	-477	2 019	-911	1 341
Capitalized own work	645	696	1 239	1 340	6 183
Other operating income	104	254	267	809	3 775
Operating income	6 319	3 275	13 066	12 554	29 558
Raw materials and consumables used ²⁾	-2 890	-2 909	-7 420	-12 266	-22 487
Other external costs ²⁾	-6 832	-7 204	-14 088	-15 634	-31 855
Personnel costs	-6 503	-7 022	-12 694	-14 006	-26 684
Depreciation/amortization of intangible assets and tangible assets	-890	-866	-1 784	-1 576	-3 370
Other operating expenses	-291	-70	-380	-657	-1 087
Operating expenses	-17 406	-18 071	-36 366	-44 140	-85 483
Operating loss	-11 087	-14 795	-23 300	-31 585	-55 925
Interest income	13	27	23	29	604
Interest expenses	-784	-805	-1 671	-1 614	-1 654
Total result of financial items	-771	-778	-1 648	-1 585	-1 051
Loss after financial items	-11 858	-15 573	-24 948	-33 170	-56 976
Tax on earnings	0	0	0	0	0
Net income	-11 858	-15 573	-24 948	-33 170	-56 976

Balance Sheet			
KSEK	2023	2022	2022
	30 Jun	30 Jun	31-dec
ASSETS			
Non-current assets			
Intangible assets	11 875	12 846	12 241
Property, plant and equipment	101 738	103 379	102 784
Financial assets	430	2 066	427
Total non-current assets	114 043	118 291	115 452
Current assets			
Inventories and products in progress	12 015	17 398	10 198
Accounts receivable	3 545	6 891	4 430
Other current receivables ²⁾	8 350	6 393	7 295
Cash and cash equivalents	5 651	22 895	24 126
Total current assets	29 561	53 577	46 049
TOTAL ASSETS	143 604	171 868	161 501
EQUITY AND LIABILITIES			
Equity			
<i>Restricted equity</i>			
Share capital	34 335	7 037	28 561
Fund, development expenditure	9 298	5 616	8 130
<i>Non-restricted equity</i>			
Share premium reserve	694 730	691 185	694 939
Accumulated profit/loss	-662 310	-601 652	-604 166
Operating income for the period	-24 948	-33 170	-56 976
Total equity	51 105	69 015	70 488
Liabilities			
Non-current liabilities			
Non-current interest-bearing liabilities ²⁾	66 827	46 753	63 783
EU contribution	2 400	3 839	2 375
Total non-current liabilities	69 227	50 591	66 159
Current liabilities			
Current interest-bearing liabilities	300	18 067	300
Accounts payable	5 629	7 523	8 612
Other current liabilities ²⁾	17 344	26 671	15 942
Total current liabilities	23 273	52 261	24 854
TOTAL EQUITY AND LIABILITIES	143 604	171 868	161 501

¹⁾ The company has an ongoing insurance claim linked to Gullhaug Torg 5 in Oslo, Norway. The company estimates the cost to replace the damaged glass to be between SEK 3.5 to 4 million. The company's assessment is that the costs of replacing the damaged glass will be covered by the company's insurance or by the insurance of other parties involved in the matter. The company assesses it to be a contingent liability and has not reserved for either costs or income from insurance as per March 31, 2023, since the company is still awaiting the decision by the insurance company.

²⁾ Of which KSEK 63,053 refers to soft loans from the Swedish Energy Agency.

Cash Flow Statement				
KSEK	2023	2022	2023	2022
	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun
OPERATING ACTIVITIES				
Profit/loss before tax	-11 087	-14 795	-23 299	-31 585
Financial income and expenses	-304	-781	-1 649	-1 588
<i>Adjustments for non-cash items:</i>				
Contribution from EU	0	0	0	0
Capital loss sold fixed assets	0	0	0	0
Depreciation/amortization and impairment	890	866	1 784	1 576
Cash flow from operating activities before changes in working capital	-10 501	-14 710	-23 164	-31 597
<i>Cash flow from changes in working capital</i>				
Increase(-)/decrease(+) inventories	-1 376	-3 567	-1 817	-6 387
Increase(-)/decrease(+) accounts receivable	1 373	3 002	885	1 966
Increase(-)/decrease(+) current receivables	-1 238	1 451	-1 055	963
Increase(+)/decrease(-) accounts payable	-2 922	-5 509	-2 983	-249
Increase(+)/decrease(-) current liabilities ¹⁾	-486	-3 638	1 414	-844
Cash flow from changes in working capital	-4 649	-8 261	-3 556	-4 551
Cash flow from operating activities	-15 150	-22 971	-26 720	-36 148
INVESTING ACTIVITIES				
Acquisition of intangible assets	-193	-2 256	-372	-3 070
Acquisition of property, plant and equipment	0	-798	0	-1 096
Sale of property, plant and equipment	0	0	0	0
Cash flow from investing activities	-193	-3 055	-372	-4 167
FINANCING ACTIVITIES				
New share issue	0	-389	5 618	44 485
Raising of a loan	4 335	0	3 000	0
Repayment of leasing debt	0	-83	0	-126
Cash flow from financing activities	4 335	-472	8 618	44 359
CASH FLOW FOR THE PERIOD	-11 008	-26 498	-18 474	4 044
CASH AND CASH EQUIVALENTS AT START OF THE PERIOD	16 659	49 383	24 126	18 851
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	5 651	22 895	5 651	122 895

Statement of changes in equity					
	Share capital	Fund, development expenditure	Share premium reserve	Accumulated profit/loss	Total equity
KSEK					
Equity Jan 1, 2022	3 408	5 616	650 330	-601 652	57 701
New share issues	3 629		50 808		54 437
New share issue fees			-9 953		-9 953
Fund for development expenditure					0
Operating income for the period				-33 170	-33 170
Equity Dec 31, 2022	7 037	8 130	691 185	-634 822	69 015
	Share capital	Fund, development expenditure	Share premium reserve	Accumulated profit/loss	Total equity
KSEK					
Equity Jan 1, 2023	28 561	8 130	694 939	-661 142	70 488
New share issues	5 774				5 774
New share issue fees			-210		-210
Fund for development expenditure		1 168		-1 168	0
Operating income for the period				-24 948	-24 948
Equity Dec 31, 2023	34 335	9 297	694 730	-687 258	51 104
<p>Among the company's liabilities is a soft loan from the Swedish Energy Agency which, according to the loan agreement and the regulations set out in the Swedish Companies Act (25:14), may be eliminated upon preparation of a balance sheet for liquidation purposes. The utilized soft loan from the Swedish Energy Agency amounted to SEK 47.6 million. Equity taking into account the soft loan, i.e. adjusted equity, amounted to SEK 110.6 million (132.6) as per December 31, 2022, and SEK 118.1 million as per December 31, 2021.</p>					

NOTES

Note 1 Accounting Principles

ChromoGenics prepares its annual accounts in accordance with the Swedish Annual Accounts Act and the general guidelines of the Swedish Accounting Standards Board set out in BFNAR 2012:1, Annual Accounts and Consolidated Accounts (K3). The year-end report has been prepared in accordance with the accounting and valuation principles that were applied in the company's most recent annual report.

Income Statement per isolated quarter				
KSEK	2023	2023	2023	2022
	Iso. Q1	Iso. Q 2	Jan-Jun	Jan-Jun
Net sales	5 800	3 741	6 943	21 392
Change in inventories of products in progress	190	1 829	2 251	2 445
Capitalized own work	595	645	4 843	2 067
Other operating income	163	104	2 966	950
Gross operating income	6 748	6 319	17 004	26 854
Raw materials and consumables used	-4 530	-2 890	-10 222	-18 499
Other external costs	-7 256	-6 832	-16 220	-16 098
Personnel costs	-6 190	-6 503	-12 678	-11 206
Depreciation/amortization of intangible assets and tangible assets	-894	-890	-1 793	-1 349
Other operating expenses	-89	-291	-430	-782
Total operating expenses	-18 960	-17 406	-41 344	-47 934
Operating income	-12 212	-11 087	-24 340	-21 080
Interest income	74	13	577	38
Interest expenses	-952	-784	-37	-2 006
Total financial items	-878	-771	540	-1 968
Operating income after financial items	-13 090	-11 858	-23 800	-23 048
Tax	0	0	0	0
Net income	-13 090	-11 858	-23 800	-23 048
Average number of shares before dilution /split or of shares 100:1	144 088 276	144 088 276	144 088 276	17 037 595
Average number of shares after dilution ^{1,2,3,4)}	144 088 276	144 088 276	144 088 276	26 152 090
Outstanding shares at the end of the reporting period before dilution ^{1, 2)}	171 675 816	171 675 816	171 675 816	35 266 585
Outstanding shares at the end of the reporting period after dilution at full utilization. ²⁾	171 675 816	171 675 816	171 675 816	39 803 058
Potential shares outstanding from warrants at the end of the reporting period ³⁾	0	0	0	0
Earnings per share before dilution, SEK ^{3,4)}	-0,09	-0,07	-0,14	-1,95
Earnings per share after dilution, SEK ^{3,4)}	-0,09	-0,07	-0,14	-1,27

Notes to the above is on the next page

1) In March 2023, 48,017 warrants of series TO4 were exercised to subscribe for 21,127 shares. In conjunction 28,849,554 warrants of series TO5 were exercised to subscribe for the same amount of shares which added 28,849,554 new shares which increased the number of shares to 171,675,816. At the end of March 2023, the shares from warrants of series TO 4 and TO 5 consisted of interim shares which was included in the total number of shares outstanding at the end of the reporting period.

2) In March 2022, a rights issue was carried out that added 18,145,892 new shares to the company, increasing the number of shares to 35,183,487. In May 2022, a warrant holder of TO3 exercised their options for shares, which added 3,098 shares to the company; in addition, an emission guarantor chose to receive shares instead of cash compensation, adding another 80,000 shares to the company and increasing the number of shares to 35,266,585.

During Q4 2022, a rights issue was carried out that added 105,800,060 shares to the company. In addition, a directed issue was carried out for guarantors who chose to receive additional units instead of guarantor compensation, increasing the number of shares by a further 1,738,490 to a total of 142,805,135.

3) The rights issue during Q1 2022 was carried out in the form of units, and the rights issue resulted in 4,536,473 units consisting of 18,145,892 shares and 18,145,892 warrants (TO4). Four warrants were entitled to subscribe for 1 new share.

The rights issue during Q4 2022 was carried out in the form of units, and the rights issue entailed 21,507,710 units consisting of 107,538,550 shares and 64,523,130 warrants (TO5). One warrant was entitled to the right to subscribe for 1 new share. The subscription period for TO 4 and TO 5 was March 13-27, 2023, and resulted in an increase in the number of shares by 28,870,681 to 171,675,816. The total number of outstanding warrants including TO4 and TO5 amounted to 0 as at March 31, 2023.



ChromoGenics

We make properties more attractive

ChromoGenics AB

Ullforsgatan 15, 752 28 Uppsala, Sweden, Tel: +46 (18) 430 04 30

Email: info@chromogenics.com

[ChromoGenics](#)